Physician profile
Thomas W Smith
NPI 1215955844
$942,359.74
in general payments reported to CMS, 2019-2025
12 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208K · 2020: $67K · 2021: $72K · 2022: $188K · 2023: $361K · 2024: $25K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $277K · Consulting Fee: $102K · Travel and Lodging: $24K · Food and Beverage: $3,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $277,357.40 |
| Consulting Fee | $102,170.00 |
| Travel and Lodging | $23,658.20 |
| Food and Beverage | $3,677.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $297,817.74 | 2019-2025 | Mitraclip, Triclip, Navitor |
| Ethicon INC. | $277,299.90 | 2023 | |
| W. L. Gore & Associates, INC. | $209,883.36 | 2019-2024 | Product In Development |
| Boston Scientific Corporation | $133,194.74 | 2019-2025 | Watchman Flx |
| Biosense Webster, INC. | $20,008.83 | 2023-2025 | |
| Novo Nordisk As | $3,750.00 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $150.12 | 2019-2025 | Lifevest |
| Edwards Lifesciences Corporation | $97.43 | 2021-2024 | Evoque |
| Abiomed | $90.30 | 2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $27.68 | 2019 | |
| Amgen INC. | $25.52 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.